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Dendritic cells (DCs) comprise distinct functional
subsets including CD8 and CD8+ classical DCs
(cDCs) and interferon-secreting plasmacytoid DCs
(pDCs). The cytokine Flt3 ligand (Flt3L) controls the
development of DCs and is particularly important
for the pDC and CD8+ cDC and their CD103+ tissue
counterparts. We report that mammalian target of ra-
pamycin (mTOR) inhibitor rapamycin impaired Flt3L-
driven DC development in vitro, with the pDCs and
CD8+-like cDCs most profoundly affected. Con-
versely, deletion of the phosphoinositide 3-kinase
(PI3K)-mTOR negative regulator Pten facilitated
Flt3L-driven DC development in culture. DC-specific
Pten targeting in vivo caused the expansion of CD8+
and CD103+ cDC numbers, which was reversible by
rapamycin. The increased CD8+ cDC numbers
caused by Pten deletion correlated with increased
susceptibility to the intracellular pathogen Listeria.
Thus, PI3K-mTOR signaling downstream of Flt3L
controls DC development, and its restriction by
Pten ensures optimal DC pool size and subset
composition.
INTRODUCTION
Dendritic cells (DCs) provide the key link between innate and
adaptive immunity by efficiently recognizing pathogens through
pattern recognition receptors such as Toll-like receptors, and
priming pathogen-specific immune responses. TheDCcompart-
ment comprises several distinct subsets, with their total and rela-
tive numbers maintained constant throughout adult life (Merad
and Manz, 2009; Pulendran et al., 2008). In the lymphoid organs
of mice, the CD8 classical or conventional DCs (cDCs) effi-
ciently present major histocompatibility complex (MHC) class II
(MHC II)-restricted exogenous antigens to CD4+ T cells.
In contrast, the CD8+ cDCs can prime cytotoxic CD8+ T cells
due to their ability to process dead or dying cells and cross-present antigens on MHC class I molecules (den Haan et al.,
2000). Consistent with these properties, CD8+ DCs are critical
for the capture, transport, and presentation of intracellular path-
ogens such as Listeria monocytogenes (LM) (Neuenhahn et al.,
2006). The same dichotomywas documented in tissues, in which
the CD103+ cDC subset serves as a functional and genetic coun-
terpart of CD8+ cDCs (Bedoui et al., 2009b; Bogunovic et al.,
2009; Ginhoux et al., 2009; Varol et al., 2009). In addition to
cDCs, plasmacytoid dendritic cells (pDCs) efficiently recognize
viral nucleic acids and secrete large amounts of type I interferon
(IFN) and other cytokines.
Both cDCs and pDCs develop through a distinct cellular
pathway involving a common DC progenitor (CDP, or pro-DC)
in the bone marrow (BM) (Naik et al., 2007; Onai et al., 2007).
The CDP gives rise to pDCs directly in the BM and produces
a common cDC precursor (pre-DC) that differentiates into
cDCs in the lymphoid organs through subset-specific intermedi-
ates (Bedoui et al., 2009a; Liu et al., 2009; Naik et al., 2006). This
common pathway of DC development critically depends on
cytokine Flt3 ligand (Flt3L), which signals through its receptor
Flt3 expressed on CDPs, pre-DCs, and their progeny. Both
cDC and pDC numbers are reduced in the lymphoid organs of
Flt3L- or Flt3-deficient animals (McKenna et al., 2000; Tussiwand
et al., 2005; Waskow et al., 2008), suggesting a key role of Flt3 in
DC development from CDPs. In the tissues, the CD8+-like
CD103+ cDCs preferentially require Flt3 for their development
(Bogunovic et al., 2009; Ginhoux et al., 2009; Varol et al.,
2009). Conversely, administration of Flt3L causes a substantial
expansion in numbers of the DC compartment (Maraskovsky
et al., 1996), particularly of the CD8+ cDCs (Bedoui et al.,
2009a; O’Keeffe et al., 2002; Vollstedt et al., 2004) and the cor-
responding CD103+ tissue DCs (Varol et al., 2009). Thus, Flt3
provides an essential signal for the development and homeo-
stasis of DCs, particularly of the CD8+ and CD103+ cDCs.
However, the molecular basis of Flt3 signaling in the DC lineage
is poorly understood, and the signal transduction pathways
downstream of Flt3 remain to be elucidated.
The phosphoinositide 3-kinase (PI3K) pathway is activated by
multiple growth factors and cytokines to control metabolism and
promote survival, proliferation, and/or differentiation (Engelman
et al., 2006). Receptor-mediated activation of PI3K family
kinases generates inositol phospholipids that activate theImmunity 33, 597–606, October 29, 2010 ª2010 Elsevier Inc. 597
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mTOR Mediates Flt3L Signaling in Dendritic Cellsprotein kinase Akt, which phosphorylates multiple substrates
including Foxo transcription factors, glycogen synthase kinase
(GSK3b), and the mammalian target of rapamycin (mTOR).
mTOR is a serine and threonine kinase that serves as a nutrient
and energy sensor regulating protein metabolism. The PI3K-Akt-
mediated activation of mTOR leads to the phosphorylation of
ribosomal protein S6, a key regulator of ribosome biogenesis,
protein translation, and cell size. The activity of PI3K-Akt
pathway is tightly controlled by multiple negative regulators
and feedback loops. A key cell-intrinsic inhibitor of Akt signaling
is phosphatase and tensin homolog (Pten), a lipid phosphatase
that prevents Akt activation by dephosphorylating PI3K-gener-
ated inositol phospholipids. The deletion of Pten leads to the
constitutive activation of PI3K-Akt signaling and is a common
event in malignant transformation. For instance, constitutive or
inducible Pten deletion in the BM causes major hematopoietic
abnormalities, myeloid leukemia, and/or T cell lymphoma
(Yilmaz et al., 2006; Zhang et al., 2006).
PI3K-mTOR has emerged as an important signaling pathway
regulating both innate and adaptive immunity (Thomson et al.,
2009; Weichhart and Sa¨emann, 2009). In the DC lineage, the
role of mTOR signaling has been studied largely in the context
of Toll-like receptor (TLR)-induced cytokine secretion. Inmyeloid
cells and cDCs, PI3K-mTOR was shown to promote maturation
(Hackstein et al., 2003) and facilitate anti-inflammatory
responses such as secretion of interleukin-10 (IL-10) (Ohtani
et al., 2008; Weichhart et al., 2008), whereas in pDCs, it is
required for TLR-induced type I interferon production (Cao
et al., 2008; Guiducci et al., 2008). In this work, we explored
the role of PI3K-mTOR signaling in DC development and homeo-
stasis. We now report that mTOR signaling is induced by Flt3L
and is required in vitro for Flt3L-driven development of DCs,
particularly of pDCs and CD8+ cDC equivalents. Conversely,
the activation of PI3K-mTOR signaling by deletion of Pten accel-
erated Flt3L-driven DC development in vitro and caused the
expansion of CD8+ and CD103+ cDC numbers in vivo. Our
results suggest that PI3K-mTOR pathway is essential for Flt3-
mediated DC development, whereas DC-intrinsic expression of
Pten restricts PI3K-mTOR signaling to maintain optimal DC
subset composition.
RESULTS
Rapamycin Blocks Flt3L-Induced DC Development
in Culture
DC development can be faithfully recapitulated in Flt3L-supple-
mented BM cultures, which give rise to pDCs and the two cDC
subsets (Naik et al., 2005). The addition of mTOR inhibitor rapa-
mycin to these cultures severely reduced the numbers of all DC
subsets at the endpoint (Figure 1A). The analysis of CFSE-
labeled BM cultures on day 3 (Figure 1B) showed that rapamycin
blocked the proliferation of DC and pDC progenitors including
CD43hi pro-DCs and CD43+ CD11c+ pre-DCs (Naik et al.,
2007). In contrast, rapamycin did not prevent DC development
in GM-CSF-supplemented BM cultures (Figure S1 available on-
line), although it affected the maturation status of the resulting
CD11b+ DCs as described previously (Hackstein et al., 2003).
The pDC population was particularly affected by rapamycin,
even when the drug was added at lower concentration598 Immunity 33, 597–606, October 29, 2010 ª2010 Elsevier Inc.(Figure 1C) or at a later time point (day 3, Figure 1D). The prolif-
eration of DC and pDC progenitors was not affected in the latter
case, suggesting an additional rapamycin effect on pDCmatura-
tion (not shown). Among the cDC subsets, the CD11blo CD24+
equivalents of CD8+ cDCs were more affected by lower rapamy-
cin concentrations than the CD11bhi equivalents of CD8 cDCs.
Thus, mTOR activity is essential for Flt3L-dependent develop-
ment of all DC in vitro, with pDCs and CD8+-like cDCs being
most sensitive to mTOR inhibition.Pten Deletion in the Bone Marrow Facilitates
Flt3L-Induced DC Development
To activate PI3K-mTOR signaling during DC development, we
deleted PI3K inhibitor Pten in the adult BM by using tamoxifen-
inducible Gt(ROSA)26Sor-CreER deleter strain. We adminis-
tered tamoxifen to Ptenfl/fl Gt(ROSA)26Sor-CreER+ mice to
induce global Pten deletion (PtenD), and 5 days later the BM
was cultured with Flt3L. The PtenD BM cultures showed greatly
accelerated DC development, yielding phenotypically mature
pDCs and cDCs as early as day 5 (Figure 2A). At the endpoint
(days 8–9), the absolute numbers of resulting DCs were
increased more than 10-fold in PtenD BM cultures (day 8,
Figure 2B). Importantly, Pten deletion partially restored DC
development in the presence of rapamycin (Figure S2), confirm-
ing the functional hyperactivation of mTOR signaling after Pten
loss. No acceleration or increased DC yield were observed in
GM-CSF-supplemented BM cultures (Figure S2). Thus, Pten
deletion in hematopoietic progenitors facilitates Flt3L-driven
development of all DC subsets in culture.
To test the effect of Pten deletion on DC development in vivo,
we reconstituted irradiated recipients with the BM from tamox-
ifen-induced mice. The chimeras reconstituted with PtenD BM
showed the expected hematopoietic abnormalities such as
myeloid shift and impaired B cell development (Zhang et al.,
2006), confounding the analysis of absolute cell numbers.
Notably, the proportion of CD8+ cDCs was increased >3-fold
among PtenD donor-derived splenocytes, whereas the fractions
of pDCs and CD8- cDCs were unchanged (Figure 2C). A similarly
increased fraction of CD8+ cDCs was observed in the spleens of
donor PtenDmice 5 days after tamoxifen administration (data not
shown). Thus, Pten deletion in the hematopoietic compartment
in vivo favors the development of CD8+ cDCs, the subset prefer-
entially expanded by Flt3L administration.Flt3 Signaling Activates mTOR in DCs
The observed correlation between mTOR signaling and Flt3L-
driven DC development prompted us to analyze mTOR activity
in DCs in vivo. As a readout, we measured phosphorylated S6
(p-S6) in DCs after instant fixation of freshly isolated splenocytes
(Figure 3A). In naive animals, CD8+ cDCs showed higher basal
amounts of pS6 (Figure 3A). The injection of recombinant Flt3L
induced a robust and transient pS6 signal in the CD11c+ DCs
but not in other cell types, reflecting DC-specific Flt3 expression
(Figure 3B). In contrast, TLR ligand administration induced a pro-
longed pS6 signal in multiple cell types (data not shown).
Notably, Flt3L-induced p-S6 signal was higher and more sus-
tained in CD8+ compared to CD8 cDCs, consistent with the
preferential expansion of this subset by Flt3L. These data
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Figure 1. Rapamycin Inhibits Flt3L-Driven DC
Development In Vitro
(A) The effect of rapamycin on DC development in vitro.
Wild-type BM was cultured in the presence of Flt3L with
or without 10 ng/ml rapamycin and analyzed by flow cy-
tometry on day 8 for the resulting pDCs (CD11c+ B220+
CD11b), CD8-like cDCs (CD11c+ B220 CD11bhi) and
CD8+-like cDCs (CD11c+ B220 CD11blo). Absolute cell
numbers per 2 3 106 input BM cells (mean ± SD of three
independent cultures) are shown; *p < 0.05; **p < 0.01.
(B) The effect of rapamycin on DC progenitor expansion.
CFSE-labeled BM cells were cultured with Flt3L with or
without rapamycin and analyzed on day 3. Highlighted
are CFSE-diluting pro-DCs with high or low CD43 expres-
sion (upper panels) and CFSElo CD11c+ pre-DCs (lower
panels), with average percentages ± range of two indepen-
dent cultures.
(C) The effect of rapamycin at low doses. BM cells were
cultured with Flt3L and the indicated doses of rapamycin.
Shown are staining profiles on day 8, highlighting CD11c+
B220+ pDCs (top) and CD24+ CD11blo CD8+-like cDCs
among the gated CD11c+MHC II+ cDCs (bottom). Average
percentages ± SD of three independent cultures are indi-
cated.
(D) Time-dependent rapamycin activity in Flt3L-supple-
mented BM cultures. Rapamycin (10 ng/ml) was added
at the indicated days, and the cultures were analyzed on
day 9. A representative of four independent cultures is
shown.
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mTOR Mediates Flt3L Signaling in Dendritic Cellsshow that Flt3L induces mTOR signaling in DCs in vivo, with the
highest activity in CD8+ cDCs.
The Expansion of CD8+ cDC Numbers after DC-Specific
Pten Deletion
To activate PI3K-mTOR signaling specifically in the DC lineage,
we targeted Pten with the DC-specific Itgax-Cre deleter strain
(Figure S3). The resulting Ptenfl/fl Itgax-Cre+ animals should
lack Pten in the CD11c (Itgax)-expressing DC (DC-PtenD).
Indeed, DC-PtenDmice carrying a fluorescent Cre reporter allele
showed Cre recombination in nearly all cDCs but only in 4%–
12% of T and B lymphocytes. In older DC-PtenD animals, the
‘‘leaky’’ Pten loss in T lymphocytes eventually caused T cellImmunity 33, 59lymphomas and death; therefore only young
adult mice (4–10 weeks) were used for analysis.
The expression of Pten was nearly abolished in
cDCs andmarkedly reduced in pDCs but normal
in myeloid non-DCs, supporting a DC-specific
Pten deletion. In vitro, DC-PtenD BM-derived
cDCs showed the expected hyperactivation of
the PI3K-Akt pathway, including hyperphos-
phorylated Akt and GSK3b (Figure S3).
The analysis of splenic DC subsets in naive
DC-PtenD mice revealed a 5- to 6-fold increase
in the fraction and absolute numbers of CD8+
cDCs, whereas CD8 cDC and pDCpopulations
remained normal (Figures 4A and 4B). To
confirm the cell-intrinsic nature of CD8+ cDC
expansion, we established competitive BM
chimeras from control or DC-PtenD (CD45.2)
donor mice and CD45.1 congenic competitormice. Donor chimerism reached 30%–40% in lymphocytes
and 15%–20% in myeloid cells and DCs (Figure S3). Even at
this relatively low chimerism, a prominent expansion of CD8+
cDCs was observed in DC-PtenD-derived splenocytes but
not in control-derived or competitor-derived splenocytes (Fig-
ure 4C). Thus, the DC-specific loss of Pten leads to the cell-
intrinsic expansion of CD8+ cDC numbers, recapitulating the
effect of global Pten deletion. Recently, Baron et al. used
Cx3cr1-EGFP reporter strain to subdivide CD8+ cDCs into two
populations and showed that only theCx3cr1-EGFP population
represents Flt3L-responsive, cross-presenting CD8+ cDCs (Bar-
On et al., 2010). The analysis of Cx3cr1-EGFP+ DC-PtenD mice
showed the increase of EGFP- but not of EGFP+ CD8+ cDCs7–606, October 29, 2010 ª2010 Elsevier Inc. 599
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Figure 2. Pten Deletion in the BM Facilitates
DC Development
Global Pten deletion was induced by tamoxifen
administration to Ptenfl/fl Gt(ROSA)26Sor-CreER+
animals (PtenD) or littermate controls (Ctrl) 5 days
prior to BM isolation.
(A) DC development in Flt3L-supplemented BM
cultures on day 5. Shown are staining profiles
representative of two independent experiments,
with total live cells (forward versus side scatter
gate), CD11c+ B220+ pDCs, CD11c+ B220
cDCs and their subsets highlighted.
(B) DC development in Flt3L-supplemented BM
cultures at the endpoint. Cultures described in (A)
were analyzed on days 8–9. Shown are representa-
tive staining profiles of total live cells, and fold
increase of the absolute DC numbers in PtenD over
control cultures (three independent experiments).
(C) DC development in vivo in the BM chimeras.
BM cells from each tamoxifen-treated animal
(one control and three PtenD) were transferred
into two irradiated recipients, and splenic DCs were analyzed 6 weeks thereafter. Shown are representative staining profiles of donor-derived (CD45.2+)
DCs, and the fractions of cDCs (CD11chi MHC II+ CD8+ or CD8) and pDCs (CD11clo B220+ Bst2+) among the total donor-derived splenocytes.
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Figure 3. mTOR Signaling in DCs In Vivo
(A) The expression of phosphorylated S6 protein (p-S6) in the splenocytes of
naive wild-type mice. Shown is the definition of cDC subsets in ex vivo spleno-
cytes after instant fixation, and p-S6 expression in T cells (CD90+), B cells
(B220+ CD11c), monocytes or macrophages (M, CD11blo CD11c), and
cDCs. Positive staining threshold is indicated by the dotted line.
(B) The induction of p-S6 by Flt3L in vivo. Shown are histograms of intracellular
p-S6 fluorescence in the indicated cell types 15 or 60 min after Flt3L adminis-
tration.
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mTOR Mediates Flt3L Signaling in Dendritic Cells(Figure 4D), confirming that the increase in numbers is specific to
the Flt3L-responsive CD8+ cDC subset.
Next, we sought to determine the developmental origin of the
observed CD8+ cDC proliferation. BrdU pulse-chase experi-
ments revealed normal incorporation and dilution rates in the
CD8+ cDCs (not shown), suggesting that Pten-deficient mature
cDCs have normal cell division and turnover. The CD11clo MHC
II Cx3cr1-EGFP+ pre-cDCs (Liu et al., 2009) were not increased
in DC-PtenD spleens (Figure S3), consistent with inefficient Cre
recombination in early cDC progenitors (Caton et al., 2007).
In contrast, we observed the expansion of MHCII+ CD24hi
CD11clo CD8loCx3cr1-EGFP population probably representing
immature CD8+ cDCs (Figure 4E). A comparable CD11clo imma-
ture population was not obvious among the MHCII+ CD24lo cells
encompassing CD8 cDCs in control or DC-PtenD mice. Thus,
Pten loss causes the expansion of CD8+ cDC numbers that orig-
inates at the immature CD8lo differentiation stage.
The Expansion of CD103+ cDC Numbers
in DC-PtenDMice
The CD103+ cDC subset in tissues represents the functional and
genetic equivalent of CD8+ cDCs and is strongly dependent on
Flt3 signaling. As shown in Figure 5, the fraction and absolute
numbers of CD103+ CD11b cDCs were increased in the
thymus, liver, lung, and intestinal lamina propria of DC-PtenD
mice. This observation was confirmed by the analysis of
Cx3cr1-EGFP+ DC-PtenD mice, in which the corresponding
Cx3cr1-EGFP CD103+ cDC population was similarly ex-
panded. This resulted in the significantly increased ratio of
CD103+ to CD103 cDCs in these organs (Figure 5C) as well
as in the Peyer’s patches and mesenteric lymph nodes (not
shown). Thus, Pten deletion results in the expansion of CD8+-
like cDCs both in lymphoid organs and in tissues.
The Expansion of Pten-Deficient CD8+ cDC Numbers
Is mTOR Dependent
We tested whether the mTOR activity was mediating the CD8+
cDC expansion caused by Pten loss. Consistent with the600 Immunity 33, 597–606, October 29, 2010 ª2010 Elsevier Inc.in vivo phenotype, the CD11b-CD24+ population of CD8+-like
cDCs was increased in Flt3L-supplemented cultures of the
DC-PtenD BM; this expansion was reduced by rapamycin
(Figure 6A). As with the global Pten deletion, DC-PtenD BM
cultures showed partial rescue of CD24+ DC development in
the presence of rapamycin, confirming mTOR activation.
Furthermore, daily administration of rapamycin reduced the
CD8+ cDC compartment of DC-PtenD mice almost to control
numbers (Figures 6B and 6C). Thus, the expansion of CD8+
cDC numbers after DC-specific Pten deletion requires the acti-
vation of mTOR. To test whether mTOR activation alone would
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Figure 4. DC-Specific Pten Deletion Causes the Expansion of CD8+
cDCs
(A) Staining profiles of splenic DC populations in Ptenfl/fl Itgax-Cre+ animals
with DC-specific Pten deletion (DC-PtenD) and in littermate controls (Ctrl),
highlighting CD11clo Bst2+ pDCs, CD11chi MHC II+ cDCs and their subsets.
(B) The fraction and absolute number of cDC subsets in DC-PtenD and control
spleens (mean ± SD, n = 10–11). The p values of statistically significant differ-
ences are indicated.
(C) The analysis of DCs in hematopoietic chimeras reconstituted with amixture
of the control or DC-PtenD BM (CD45.2+) and wild-type CD45.1+ competitor
BM. Shown are representative staining profiles and the absolute numbers of
donor- and competitor-derived splenic cDC subsets (mean ± SD of three
recipient animals).
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mTOR Mediates Flt3L Signaling in Dendritic Cellsaffect DC development, we performed DC-specific targeting of
Tsc1, a key negative regulator of mTOR. The Tsc1fl/fl Itgax-
Cre+ mice harbored a normal DC compartment (Figure S4), sug-
gesting that mTOR activity is necessary but not sufficient for
CD8+ cDC expansion.DC-Specific Pten Deletion Impairs Control of Listeria
Infection
The expansion of DC compartment by Flt3L and other cytokines
paradoxically impairs immunity to intracellular bacteria such as
Listeria (LM) and pneumococci (Alaniz et al., 2004; Winter
et al., 2007). We therefore tested the ability of DC-PtenD mice
to control LM infection, by using the attenuated ovalbumin-ex-
pressing LM (LM-OVA). At low LM-OVA doses DC-PtenD mice
survived until day 6 but showed a severe disorganization of the
spleen architecture with necrotic foci, hypocellularity, and disso-
lution of lymphoid follicles (Figure 7A). At higher LM-OVA doses,
control mice survived and cleared the infection by day 6,
whereas all DC-PtenD mice became moribund and harbored
high bacterial titers in the spleens and livers (Figure 7B). By
immunochemistry, DC-PtenD spleens showed a greatly
increased bacterial load as early as 24 hr after infection
(Figure 7C). Similarly, at 36 hr high LM titers were detected in
the livers of all DC-PtenD mice, whereas most control livers
remained sterile (data not shown). On the other hand, both the
initial clustering of OVA-specific CD8+ T cells and their subse-
quent expansion were unaffected, suggesting that Pten-defi-
cient cDCs can efficiently prime T cells (Figure S5). These data
demonstrate that DC-specific deletion of Pten causes CD8+
cDC expansion but increases susceptibility to LM, similar to
cytokine-induced DC expansion. Thus, Pten expression in DCs
controls optimal DC subset homeostasis to ensure protection
against bacterial infections.DISCUSSION
DCs represent the only immune cell type expressing Flt3
receptor throughout all developmental stages as well as in
mature cells (Karsunky et al., 2003). Accordingly, Flt3L is a key
regulator of steady-state DC development, facilitating the prolif-
eration of earliest DC progenitors in the BM (D’Amico and Wu,
2003; Karsunky et al., 2003) and the differentiation of pre-DCs
intomature DCs in the periphery (Waskow et al., 2008). However,
the pathways transducing Flt3 signals in DCs have been poorly
characterized. Although transcription factor Stat3 is important
for Flt3-driven pDC and cDC development (Laouar et al., 2003;
Onai et al., 2006), more proximal signaling pathways down-
stream of Flt3 remain unknown. The PI3K-mTOR signaling plays
an important role downstream of the constitutive Flt3 receptor(D) Splenic cDC subsets in Cx3cr1-EGFP+ DC-PtenD and littermate control
mice. Shown are staining profiles of CD11chi MHC II+ cDCs with EGFP+ and
EGFP- CD8+ cDC subsets highlighted and absolute numbers of cDC subsets
(mean ± SD, n = 4–5).
(E) Immature splenic cDC populations in DC-PtenD and control mice. Shown
are staining profiles of gated MHC II+ CD24+ or CD24– populations containing
mature CD11chi cDC subsets as well as CD11clo CD8lo immature cDCs
(mean ± SD of three animals).
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Figure 5. The Expansion of CD103+ cDCs after Pten Deletion
(A) The CD103+ versus CD11b+ cDC subset distribution in the tissues of DC-
specific DC-PtenD mice. Shown are representative staining profiles of DAPI
CD45+ CD11chi MHC II+ cDCs from the indicated tissues of Cx3cr1-EGFP+
DC-PtenD and control mice. The populations of CD103+ and CD11b+ or
Cx3cr1-EGFP+ DCs are highlighted; the intestinal lamina propria (LP) contains
an additional CD103+ CD11b+ population.
(B) Absolute numbers of CD103+ cDCs in individual DC-PtenD mice shown by
pairwise comparison to the corresponding littermate control.
(C) The ratio of CD103+ CD11b to CD103 CD11b+ fractions among cDCs
from control and DC-PtenD mice (mean ± SEM of 8–9 animals for all tissues
except intestinal LP, for which n = 3).
Immunity
mTOR Mediates Flt3L Signaling in Dendritic Cellsactivation in myeloid leukemias (Mohi et al., 2004), and activates
Stat3 in TLR-stimulated cells (Weichhart et al., 2008). We there-
fore tested its role in the physiological Flt3 signaling during DC
development. We found that mTOR signaling is activated by
Flt3 in DCs, and is essential for Flt3L-mediated but not GM-
CSF-mediated DC development in vitro. Conversely, genetic
activation of PI3K-mTOR by the loss of Pten facilitated Flt3L-
driven DC development in vitro, and caused in vivo expansion
of CD8+ cDCs in a manner resembling Flt3L administration.
This genetic evidence collectively suggests that the PI3K-
mTOR pathway represents a key transducer of Flt3L-Flt3 signals
in DCs.602 Immunity 33, 597–606, October 29, 2010 ª2010 Elsevier Inc.In cultures of total BM cells, Flt3L promotes proliferation of
common DC and pDC progenitors (Naik et al., 2007) and drives
the development of all DC subsets (Naik et al., 2005). We found
that mTOR inhibitor rapamycin severely impaired DC develop-
ment in BM cultures by blocking Flt3L-driven proliferation of
early progenitors. This effect was due to on-target rapamycin
activity because it was observed at concentrations commonly
used for mTOR inhibition (Hackstein et al., 2003; Cao et al.,
2008; Ohtani et al., 2008) and was partially rescued by Pten
deletion. The requirement for mTOR in Flt3L signaling may be
particularly evident in BM cultures, given that DC development
in this system is rapid, inducible, and driven solely by Flt3L.
Furthermore, these in vitro results are in line with the reported
50% reduction of total DC numbers in vivo after prolonged ra-
pamycin administration tomice (Hackstein et al., 2003). Although
all DC subsets were affected by rapamycin, the pDCs were
particularly sensitive, consistent with the more severe decrease
of pDCs in Flt3-deficient or mutant animals (Eidenschenk et al.,
2010; Waskow et al., 2008). Among cDCs, the CD24hi CD8+-
like DCs were more susceptible to mTOR blockade, in agree-
ment with the selective role of Flt3 in the development of CD8+
and CD103+ cDCs (Bogunovic et al., 2009; Ginhoux et al.,
2009; Varol et al., 2009). Conversely, PI3K-mTOR hyperactiva-
tion caused by deletion of Pten in the BM ameliorated the effect
of rapamycin and greatly increased Flt3L-driven DC develop-
ment in BM cultures. Both rapamycin and Pten deletion acted
specifically in Flt3L cultures and did not affect DC development
driven by GM-CSF. Overall, the efficiency of Flt3-driven DC
development in BM cultures directly correlated with the
blockade or hyperactivation of mTOR activity, suggesting that
mTOR mediates Flt3 signaling in this system.
To analyze the consequences of PI3K-mTOR hyperactivation
in vivo, we deleted Pten in hematopoietic progenitors (PtenD)
or in committed DCs (DC-PtenD). In both systems, Pten deletion
caused a dramatic expansion of CD8+ cDC subset in the spleen
and a less pronounced increase of the corresponding CD103+
cDC subset in tissues. Although Pten deletion activates multiple
pathways downstreamof PI3K, the phenotypewas fully reversed
by mTOR blockade. Notably, preferential expansion of CD8+
cDCs is a hallmark of Flt3L administration in vivo, as docu-
mented in several studies (Bedoui et al., 2009a; O’Keeffe et al.,
2002; Vollstedt et al., 2004). This phenotype is unique to Flt3L,
given that other cytokines such as GM-CSF preferentially
expand CD8 cDCs (Mach et al., 2000; O’Keeffe et al., 2002).
Furthermore, only a distinct Cx3cr1-EGFP- subset of CD8+
cDCs is responsive to Flt3L (Bar-On et al., 2010), the same
subset that is specifically expanded in DC-PtenD mice. Thus,
genetic activation of PI3K-mTOR signaling in DCs recapitulates
the subset preference (albeit not the magnitude) of Flt3L-
induced DC expansion, supporting the role of mTOR in Flt3
signaling in vivo.
An important question is why Pten deletion does not increase
the number of CD8 cDCs or pDCs in vivo, as it does in BM
cultures. One possibility is that these two subsets or their
progenitor ‘‘saturate’’ their respective anatomic niches, such
as the splenic marginal zone for CD8 cDCs. Another likely
explanation is that their development does not involve extensive
proliferation between lineage commitment and terminal differen-
tiation. Indeed, CD8 cDCs and pDCs are relatively poorly
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Figure 6. mTOR Blockade Reverses the Expansion
of Pten-Deficient DCs
(A) Rapamycin treatment of Flt3L-supplemented BM
cultures from DC-PtenD and control mice. Rapamycin
was added on day 3 of culture. Shown are staining profiles
of gated CD11c+ B220 cDCs highlighting the CD11blo
CD24hi CD8+ cDC-like subset (mean ± range of two inde-
pendent cultures).
(B) Rapamycin treatment of DC-PtenD and control animals.
Shown are representative staining profiles of splenic
CD11chi MHC II+ cDCs from mice treated for 7 days with
rapamycin or vehicle only.
(C) Absolute numbers of splenic cDC subsets from DC-
PtenD and control animals treated with rapamycin
(mean ± SD of 5–6 animals per group).
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mTOR Mediates Flt3L Signaling in Dendritic Cellsresponsive to Flt3L administration in vivo, yielding 2- to 3-fold
expansion at best compared to >30-fold expansion attainable
with CD8+ cDCs (O’Keeffe et al., 2002; Vollstedt et al., 2004). It
is noteworthy that the CD8 cDC expansion caused by B16-Spleen
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Immunity 33, 59Flt3L tumor cell injection (Mach et al., 2000)
may reflect an antitumor immune reaction
because it is not recapitulated by recombinant
Flt3L (O’Keeffe et al., 2002). Furthermore, trans-
genic expression of the transforming SV40 T
antigens in all CD11c+ cDCs caused selective
expansion of CD8+ but not of CD8 cDCs
(Steiner et al., 2008). Finally, DC expansion
due to Pten loss likely requires endogenousFlt3L, whose concentration is tightly regulated and may be
limiting. Thus, Pten deletion recapitulates the specificity of
Flt3L administration, but does not reach the higher threshold
required for the expansion of CD8 cDCs and pDCs in vivo.Figure 7. DC-Specific Pten Deletion Increases
Sensitivity to Listeria Infection
(A) Spleen histology of control and DC-PtenD mice on day
6 after infection with 23 104 LM-OVA bacteria (H&E stain-
ing, 253 magnification; inset, 4003 magnification). Unin-
fected control or DC-PtenD mice showed no difference
by histology (not shown).
(B) Bacterial titers on day 6 after infection with 23 105 LM-
OVA. All DC-PtenD mice were moribund and showed
prominent inflammation of the spleen and liver. Symbols
represent individual animals; N.D., not detected.
(C) Immunohistochemical analysis of the spleen 24 hr after
infection with 105 LM-OVA. Frozen spleen sections were
stained for polymerized actin, CD11c, and ovalbumin for
LM-OVA detection.
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mTOR Mediates Flt3L Signaling in Dendritic CellsThe CD8+ and CD103+ cDC subsets appears particularly
responsive to Flt3 signaling and to Pten deletion that facilitates
it. This correlates with increased mTOR signaling after Flt3L
administration and in the steady state, the latter possibly reflect-
ing endogenous Flt3L activity. Although the molecular basis for
such increasedmTOR signaling remains to be elucidated, it likely
contributes to the Flt3L responsiveness of CD8+ cDCs. Another
important factor is the presence of a Flt3-sensitive differentiation
stage specifically in this subset. Indeed, Pten deletion caused
marked expansion of MHC II+CD24+CD11cloCD8lo population,
the likely immature intermediate between pre-DCs and CD8+
CD11chi cDCs. This population at least partially overlaps with
the CD8int cDCs and with the recently identified CD24hi CD8-
precursors of CD8+ cDCs, both of which are specifically
expanded by Flt3L treatment (Bedoui et al., 2009a; O’Keeffe
et al., 2002). Furthermore, the cell-intrinsic restriction of CD8lo
precursor expansion by Pten appears necessary to maintain
the characteristic low numbers of CD8+ cDCs. A similar role of
Pten has been reported in the B cell lineage, where Pten deletion
enhances the generation of only certain B cell subsets such as
marginal zone B cells (Anzelon et al., 2003; Suzuki et al., 2003).
Thus, in both DCs and B cells Pten acts as a critical regulator
of differentiation that maintains proper ratios of peripheral cell
subsets.
This newly established function of Pten in the negative regula-
tion of CD8+ cDC numbers is critical for the optimal immune
response, as demonstrated by impaired control of Listeria infec-
tion after DC-specific Pten loss. Again, this result resembles the
consequences of Flt3L treatment, which increases susceptibility
to several pathogenic bacteria including S. pneumoniae (Winter
et al., 2007), Listeria, and M. tuberculosis (Alaniz et al., 2004).
Neither Pten deletion (this study) nor Flt3L treatment (Alaniz
et al., 2004) impaired T cell responses to Listeria, suggesting
that the T cell priming capacity of DCs remains intact. Indeed,
increased Listeria replication in Pten-targeted mice was
observed as early as 24 hr after infection, suggesting an early
defect that precedes T cell priming. Although functional DC
defects such as impaired IL-12 production are possible (Ohtani
et al., 2008), IL-12 production was relatively normal both in
Flt3L-expanded DCs (O’Keeffe et al., 2002) and in Pten-deficient
DCs (data not shown). A more likely possibility is the sheer
increase in DC numbers, which creates a larger reservoir for early
bacterial replication. Indeed, splenic cDCs provide the key
cellular niche of Listeria shortly after infection (Aoshi et al.,
2009; Aoshi et al., 2008), and CD8+ cDCs in particular are
responsible for Listeria spread and transport into the white
pulp (Neuenhahn et al., 2006). At later time points, cDCs are
prominently infected but, unlike macrophages, neither kill
bacteria nor become targets of cytotoxic T cells (Alaniz et al.,
2004). Therefore, the expansion of DCs in general and of CD8+
cDCs in particular appears detrimental for the control of bacterial
infections and must be restricted by specific regulatory mecha-
nisms. Our results identify the DC-intrinsic negative control of
PI3K-mTOR signaling by Pten as one such mechanism that
ensures proper balance of peripheral DC subsets, thereby facil-
itating optimal immune responses.
In conclusion, our study identifies a role of PI3K-mTOR
signaling as a key mediator of DC development downstream of
Flt3 and underscores the importance of its precise regulation604 Immunity 33, 597–606, October 29, 2010 ª2010 Elsevier Inc.by Pten for DC homeostasis and immunity to pathogens. These
data have implications for the therapeutic use of mTOR inhibitor
drug rapamycin, which in the long term may affect DC develop-
ment in human patients. In addition, these results suggest that
the commonly used Flt3L-induced DC expansion may not
adequately represent steady-state DC development, due to
skewed subset composition and excessive mTOR signaling in
DCs. These caveats of cytokine-induced DC expansion should
be considered in the design of DC-based therapeutic strategies.EXPERIMENTAL PROCEDURES
Animals
The Ptenfl (Trotman et al., 2003), Gt(ROSA)26Sor-CreER (Cisse et al., 2008),
Itgax-Cre (originally designated CD11c-Cre, Caton et al., 2007), and Cx3cr1-
EGFP (Jung et al., 2000) strains and crosses thereof were on C57BL/6 back-
ground (N10+). Because Itgax-Cre+ or Gt(ROSA)26Sor-CreER+ animals show
no phenotypic or functional differences from the wild-type (Caton et al., 2007
and data not shown), Cre-negative littermates were used as controls. Wild-
type C57BL/6 and CD45.1 congenic B6.SJL mice were from Taconic.
Cre recombination in Gt(ROSA)26Sor-CreER+ animals and control litter-
mates was induced by oral tamoxifen administration as described (Cisse
et al., 2008). Five days later, BM was removed, confirmed for Pten deletion
by genomic PCR and cultured in vitro or injected i.v. into lethally irradiated
B6.SJL mice. The recipients were analyzed after 6 weeks and showed >90%
donor chimerism. For competitive reconstitution from Itgax-Cre+ mice, control
or DC-PtenD BM cells were mixed 1:1 with B6.SJL BM cells and injected into
irradiated B6.SJL recipients. The resulting chimeras were analyzed
8–10 weeks later. For in vivo rapamycin treatment, mice were injected i.p.
with 30 mg rapamycin (LC Laboratories) in PBS containing 5% DMSO and
10% ethanol or with vehicle only for 7 consecutive days. For in vivo Flt3 stim-
ulation, mice were injected i.v. with 1 mg of recombinant murine Flt3L (R&D
Systems) in PBS, and the spleens were harvested at the indicated times. All
animal studies were performed in accordancewith the investigators’ protocols
approved by the respective institutional animal care and use committees.Cell Analysis
Cells were isolated ex vivo from lymphoid organs and stained for cell surface
markers as described (Caton et al., 2007; Cisse et al., 2008). The isolation and
analysis of DCs from the thymus, lymph nodes, and tissues was done as in
Bogunovic et al. (2009) and Ginhoux et al. (2009). For the analysis of S6 phos-
phorylation in vivo, splenocytes were isolated directly into PBS with parafor-
maldehyde and permeabilized with ice-cold methanol as described
(O’Gorman et al., 2009). Fixed cells were simultaneously stained for cell
surface markers and phospho-S6 Ser235-236 (clone 2F9, Cell Signaling Tech-
nology) with predetermined antibody per cell number ratios. The samples were
acquired on LSR II flow cytometer or sorted on FACSAria flow sorter (BD Im-
munocytometry Systems) and analyzed using FlowJo software (Treestar Inc.).DC Culture
For DC development in vitro, total BM cells (2 3 106/ml) were cultured for
8–10 days with 50–100 ng/ml recombinant murine Flt3L (for all experiments
involving rapamycin treatment), or with 20% supernatant of Flt3L-expressing
B16 cell line (Mach et al., 2000). CFSE labeling was done as described (Naik
et al., 2007). Rapamycin was added at 10 ng/ml unless indicated otherwise.LM-OVA Infection
Freshly grown LM-OVA (Dudani et al., 2002) was diluted in PBS and injected
i.v. at the indicated number. For LM titration, one-half of the spleen and liver
was lysed in PBS with 0.1% Tween 20 and plated on BHI (BD Biosciences)
agar plates. For histological analysis, spleens were fixed, paraffin-embedded
and stained with hematoxylin-eosin. The detection of LM-OVA in the spleens
by immunochemistry was performed as described (Aoshi et al., 2009).
Immunity
mTOR Mediates Flt3L Signaling in Dendritic CellsStatistical Analysis
Statistical significance was estimated with an unpaired, two-tailed Student’s
t test.
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